Public preferences for delayed or immediate antibiotic prescriptions in UK primary care: A choice experiment.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
08 2021
Historique:
received: 08 12 2019
accepted: 15 07 2021
revised: 14 09 2021
pubmed: 31 8 2021
medline: 11 11 2021
entrez: 30 8 2021
Statut: epublish

Résumé

Delayed (or "backup") antibiotic prescription, where the patient is given a prescription but advised to delay initiating antibiotics, has been shown to be effective in reducing antibiotic use in primary care. However, this strategy is not widely used in the United Kingdom. This study aimed to identify factors influencing preferences among the UK public for delayed prescription, and understand their relative importance, to help increase appropriate use of this prescribing option. We conducted an online choice experiment in 2 UK general population samples: adults and parents of children under 18 years. Respondents were presented with 12 scenarios in which they, or their child, might need antibiotics for a respiratory tract infection (RTI) and asked to choose either an immediate or a delayed prescription. Scenarios were described by 7 attributes. Data were collected between November 2018 and February 2019. Respondent preferences were modelled using mixed-effects logistic regression. The survey was completed by 802 adults and 801 parents (75% of those who opened the survey). The samples reflected the UK population in age, sex, ethnicity, and country of residence. The most important determinant of respondent choice was symptom severity, especially for cough-related symptoms. In the adult sample, the probability of choosing delayed prescription was 0.53 (95% confidence interval (CI) 0.50 to 0.56, p < 0.001) for a chesty cough and runny nose compared to 0.30 (0.28 to 0.33, p < 0.001) for a chesty cough with fever, 0.47 (0.44 to 0.50, p < 0.001) for sore throat with swollen glands, and 0.37 (0.34 to 0.39, p < 0.001) for sore throat, swollen glands, and fever. Respondents were less likely to choose delayed prescription with increasing duration of illness (odds ratio (OR) 0.94 (0.92 to 0.96, p < 0.001)). Probabilities of choosing delayed prescription were similar for parents considering treatment for a child (44% of choices versus 42% for adults, p = 0.04). However, parents differed from the adult sample in showing a more marked reduction in choice of the delayed prescription with increasing duration of illness (OR 0.83 (0.80 to 0.87) versus 0.94 (0.92 to 0.96) for adults, p for heterogeneity p < 0.001) and a smaller effect of disruption of usual activities (OR 0.96 (0.95 to 0.97) versus 0.93 (0.92 to 0.94) for adults, p for heterogeneity p < 0.001). Females were more likely to choose a delayed prescription than males for minor symptoms, particularly minor cough (probability 0.62 (0.58 to 0.66, p < 0.001) for females and 0.45 (0.41 to 0.48, p < 0.001) for males). Older people, those with a good understanding of antibiotics, and those who had not used antibiotics recently showed similar patterns of preferences. Study limitations include its hypothetical nature, which may not reflect real-life behaviour; the absence of a "no prescription" option; and the possibility that study respondents may not represent the views of population groups who are typically underrepresented in online surveys. This study found that delayed prescription appears to be an acceptable approach to reducing antibiotic consumption. Certain groups appear to be more amenable to delayed prescription, suggesting particular opportunities for increased use of this strategy. Prescribing choices for sore throat may need additional explanation to ensure patient acceptance, and parents in particular may benefit from reassurance about the usual duration of these illnesses.

Sections du résumé

BACKGROUND
Delayed (or "backup") antibiotic prescription, where the patient is given a prescription but advised to delay initiating antibiotics, has been shown to be effective in reducing antibiotic use in primary care. However, this strategy is not widely used in the United Kingdom. This study aimed to identify factors influencing preferences among the UK public for delayed prescription, and understand their relative importance, to help increase appropriate use of this prescribing option.
METHODS AND FINDINGS
We conducted an online choice experiment in 2 UK general population samples: adults and parents of children under 18 years. Respondents were presented with 12 scenarios in which they, or their child, might need antibiotics for a respiratory tract infection (RTI) and asked to choose either an immediate or a delayed prescription. Scenarios were described by 7 attributes. Data were collected between November 2018 and February 2019. Respondent preferences were modelled using mixed-effects logistic regression. The survey was completed by 802 adults and 801 parents (75% of those who opened the survey). The samples reflected the UK population in age, sex, ethnicity, and country of residence. The most important determinant of respondent choice was symptom severity, especially for cough-related symptoms. In the adult sample, the probability of choosing delayed prescription was 0.53 (95% confidence interval (CI) 0.50 to 0.56, p < 0.001) for a chesty cough and runny nose compared to 0.30 (0.28 to 0.33, p < 0.001) for a chesty cough with fever, 0.47 (0.44 to 0.50, p < 0.001) for sore throat with swollen glands, and 0.37 (0.34 to 0.39, p < 0.001) for sore throat, swollen glands, and fever. Respondents were less likely to choose delayed prescription with increasing duration of illness (odds ratio (OR) 0.94 (0.92 to 0.96, p < 0.001)). Probabilities of choosing delayed prescription were similar for parents considering treatment for a child (44% of choices versus 42% for adults, p = 0.04). However, parents differed from the adult sample in showing a more marked reduction in choice of the delayed prescription with increasing duration of illness (OR 0.83 (0.80 to 0.87) versus 0.94 (0.92 to 0.96) for adults, p for heterogeneity p < 0.001) and a smaller effect of disruption of usual activities (OR 0.96 (0.95 to 0.97) versus 0.93 (0.92 to 0.94) for adults, p for heterogeneity p < 0.001). Females were more likely to choose a delayed prescription than males for minor symptoms, particularly minor cough (probability 0.62 (0.58 to 0.66, p < 0.001) for females and 0.45 (0.41 to 0.48, p < 0.001) for males). Older people, those with a good understanding of antibiotics, and those who had not used antibiotics recently showed similar patterns of preferences. Study limitations include its hypothetical nature, which may not reflect real-life behaviour; the absence of a "no prescription" option; and the possibility that study respondents may not represent the views of population groups who are typically underrepresented in online surveys.
CONCLUSIONS
This study found that delayed prescription appears to be an acceptable approach to reducing antibiotic consumption. Certain groups appear to be more amenable to delayed prescription, suggesting particular opportunities for increased use of this strategy. Prescribing choices for sore throat may need additional explanation to ensure patient acceptance, and parents in particular may benefit from reassurance about the usual duration of these illnesses.

Identifiants

pubmed: 34460825
doi: 10.1371/journal.pmed.1003737
pii: PMEDICINE-D-19-04469
pmc: PMC8439451
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1003737

Subventions

Organisme : Department of Health
Pays : United Kingdom

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Br J Gen Pract. 2012 Sep;62(602):e639-46
pubmed: 22947585
BMJ. 2014 Mar 06;348:g1606
pubmed: 24603565
BMJ. 2013 Oct 10;347:f5806
pubmed: 24114306
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
BMJ. 2010 Feb 05;340:c199
pubmed: 20139214
Thorax. 2001 Feb;56(2):109-14
pubmed: 11209098
Br J Gen Pract. 2003 Nov;53(496):871-7
pubmed: 14702908
Allergy. 2020 Feb;75(2):273-288
pubmed: 31049971
Cochrane Database Syst Rev. 2017 Sep 07;9:CD004417
pubmed: 28881007
BMC Health Serv Res. 2014 Aug 28;14:360
pubmed: 25167926
BMJ Open. 2016 Oct 24;6(10):e012244
pubmed: 27798010
BMJ Open. 2014 Oct 27;4(10):e006245
pubmed: 25348424
BMJ Open. 2015 Nov 27;5(11):e009748
pubmed: 26614626
Br J Gen Pract. 2013 Jul;63(612):e429-36
pubmed: 23834879
BMJ. 2017 May 22;357:j2148
pubmed: 28533265
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii36-ii43
pubmed: 29490058
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii27-ii35
pubmed: 29490059
Soc Sci Med. 2015 Jan;124:48-56
pubmed: 25461861
Patient. 2016 Dec;9(6):525-536
pubmed: 27167075
Lancet Infect Dis. 2014 Mar;14(3):213-9
pubmed: 24440616
JAMA. 2017 Jul 4;318(1):82-83
pubmed: 28672303
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii2-ii10
pubmed: 29490062
Ann Surg Oncol. 2012 Nov;19(12):3668-76
pubmed: 22875647
Med Decis Making. 2015 Jan;35(1):94-105
pubmed: 25145575
Patient. 2015 Oct;8(5):373-84
pubmed: 25726010
BMJ. 2006 Aug 12;333(7563):321
pubmed: 16847013
BMJ Open. 2016 Nov 18;6(11):e011882
pubmed: 27864242
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):19-26
pubmed: 29490060
J Antimicrob Chemother. 2018 May 1;73(5):1423-1432
pubmed: 29514268
Med Decis Making. 2016 Feb;36(2):210-22
pubmed: 26670663
Br J Gen Pract. 2007 Dec;57(545):942-7
pubmed: 18252068

Auteurs

Liz Morrell (L)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

James Buchanan (J)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.
NIHR Biomedical Research Centre Oxford, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Laurence S J Roope (LSJ)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.
NIHR Biomedical Research Centre Oxford, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Koen B Pouwels (KB)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.

Christopher C Butler (CC)

NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.
Nuffield Department of Primary Care Sciences, University of Oxford, Oxford, United Kingdom.

Benedict Hayhoe (B)

Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.

Sarah Tonkin-Crine (S)

NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.
Nuffield Department of Primary Care Sciences, University of Oxford, Oxford, United Kingdom.

Monsey McLeod (M)

NIHR Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Centre for Medication Safety and Service Quality, Pharmacy Department, Imperial College Healthcare NHS Trust, London, United Kingdom.
NIHR Imperial Patient Safety Translational Research Centre, Imperial College London, London, United Kingdom.

Julie V Robotham (JV)

Modelling and Economics Unit, National Infection Service, Public Health England, London, United Kingdom.

Alison Holmes (A)

NIHR Health Protection Research Unit in Healthcare-Associated Infections and Antimicrobial Resistance, Imperial College London, London, United Kingdom.

A Sarah Walker (AS)

NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.
NIHR Biomedical Research Centre Oxford, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Sarah Wordsworth (S)

Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, United Kingdom.
NIHR Biomedical Research Centre Oxford, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH